Actinium Pharmaceuticals (ATNM) Enterprise Value (2011 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Enterprise Value of -$42.1 million for Q1 2026, up 35.5% year-over-year from -$31.1 million in Q1 2025, and up 12.22% quarter-over-quarter from -$48.0 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Enterprise Value (2011 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Enterprise Value for 16 consecutive years, with -$42.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 35.5% year-over-year to -$42.1 million; the TTM figure through Mar 2026 stood at -$42.1 million (up 35.5% YoY), while the FY2025 annual figure was -$48.0 million, up 34.16% from the prior year.
- Enterprise Value advanced to -$42.1 million in Q1 2026 per ATNM's latest filing, from -$48.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$42.1 million in Q1 2026 and bottomed at -$116.7 million in Q2 2022.
- Historically, Enterprise Value has averaged -$79.2 million across 5 years, with a median of -$78.7 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value tumbled 41.65% — and 2026, when it surged 35.5%.
- Actinium Pharmaceuticals' Enterprise Value stood at -$109.3 million in 2022, then rose by 29.85% to -$76.7 million in 2023, then advanced by 4.92% to -$72.9 million in 2024, then soared by 34.16% to -$48.0 million in 2025, then climbed by 12.22% to -$42.1 million in 2026.
- Business Quant data shows ATNM's Enterprise Value at -$42.1 million in Q1 2026, -$48.0 million in Q4 2025, and -$53.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 2.12 Bn |
| 10 | Actinium Pharmaceuticals | 35.48 Mn | 35.48 Mn | - | -36.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.47 Mn |
| Mar 31, 2026 | -42.13 Mn |
| Dec 31, 2025 | -48.00 Mn |
| Sep 30, 2025 | -53.39 Mn |
| Jun 30, 2025 | -59.93 Mn |
| Mar 31, 2025 | -65.33 Mn |
| Dec 31, 2024 | -72.90 Mn |
| Sep 30, 2024 | -78.66 Mn |
| Jun 30, 2024 | -86.04 Mn |
| Mar 31, 2024 | -84.06 Mn |
| Dec 31, 2023 | -76.68 Mn |
| Sep 30, 2023 | -82.98 Mn |
| Jun 30, 2023 | -91.28 Mn |
| Mar 31, 2023 | -94.92 Mn |
| Dec 31, 2022 | -109.31 Mn |
| Sep 30, 2022 | -112.21 Mn |
| Jun 30, 2022 | -116.72 Mn |
| Mar 31, 2022 | -72.41 Mn |
| Dec 31, 2021 | -78.22 Mn |
| Sep 30, 2021 | -82.52 Mn |